Back to results
US 11,406,703 B2Granted
Human cytomegalovirus vaccine
AssigneeModernaTX, Inc.
InventorsJack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
Life of this patent
Estimating the term…
Abstract
Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
Claims30
A human cytomegalovirus (hCMV) immunogenic composition comprising (a) a messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding a hCMV gH polypeptide;
- (b) a mRNA polynucleotide comprising an open reading frame encoding a hCMV gL polypeptide;
- (c) a mRNA polynucleotide comprising an open reading frame encoding a hCMV UL128 polypeptide;
- (d) a mRNA polynucleotide comprising an open reading frame encoding a hCMV UL130 polypeptide;
- (e) a mRNA polynucleotide comprising an open reading frame encoding a hCMV UL131A polypeptide;
- and (f) a mRNA polynucleotide comprising an open reading frame encoding a hCMV gB polypeptide, wherein:
- the molar ratio of (a):(f) within the immunogenic composition is about 1:1;
- the molar ratio of (b):(c):(d):(e) within the immunogenic composition is about 1:1:1:1;
- and
- the molar ratio of each of (a) and (f) to any one of (b), (c), (d) or (e) within the immunogenic composition is about 1.5:1 to 2:1.
6 more elements
Dependencies are inferred from the claim text.